Please login to the form below
Dsuvia
This page shows the latest Dsuvia news and features for those working in and with pharma, biotech and healthcare.
AcelRX’s potent opioid tablets set to win FDA backing for pain relief
Unlike intravenous-based opioids, Dsuvia, which is already approved in the EU, could allow for a more effective and less invasive pain reliever. ... We are pleased with the Advisory Committee’s recommendation to approve Dsuvia as a treatment in
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- FDA external report recommends actions to address US opioid crisis
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Inizio appoints Stefanie Christmas as global head of DE&I
- Rare diseases: not so rare after all
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
